Day: May 19, 2022

Posted on

Experience Parallel Search Capabilities on the HUAWEI Mate Xs 2 with Petal Search

Maximise your efficiency through the new parallel search experience

MILAN, May 19, 2022 /PRNewswire/ — With the recent launch of the HUAWEI Mate Xs 2, consumers are treated with a foldable phone that is slim and light but still equipped with HUAWEI flagship technology. The HUAWEI Mate Xs 2 introduces smart multi-window capabilities that can further expand the usage of the phone, which implements collaborative interaction between different applications to achieve better continuity. On that note, Petal Search has adopted and improved to work hand in hand with the new parallel search functions.

Parallel search experience on Petal Search increasing efficiency

Adapting to the always-on lives of today’s consumers, Petal Search allows users to double their efficiency experience a new layout of a search engine.

With Petal Search now optimised for foldable screens, users can search for an array of topics ranging from news, apps, shopping, nearby services, and many more on the 7.8-inch True-Chroma foldable display of the new HUAWEI Mate Xs 2. With one tap on the search bar, the Parallel Search function is automatically activated as details of the search is smoothly displayed across both screens in a dual-window layout. This interactive design allows users to multitask on larger screens improving efficiency even during leisure browsing.

Petal Search provides consumers with the Parallel Search function, allowing different portions of the search services that the consumer is using to be displayed on both screens at the same time. Valuable information will be doubled, complicated operations will be reduced by half, and the efficiency will be improved by 100%.

Parallel Search allows users to instantly view search results on one screen while still scrolling through for further options on the other. For example, scroll through nearby food options on one screen, while displaying detailed information of a selection option on the other, deals, menu, food photos , reviews, ordering online, etc. With such a versatile layout, consumers are able to experience a smooth and efficient browsing experience.

With online shopping being the go-to for most, research shows that roughly 51% of consumers visit up to 4 sites before deciding to purchase a product (Source: People Comparison Shop).  To aid consumers in their search, the new search function can display product details all on one page allowing easy comparison between 2 items. Furthermore, Petal Search allows users to run 2 search services simultaneously, such as video-streaming apps on one screen of the HUAWEI Mate Xs 2 while reading up on the latest news on the other.

All-In-One Search for an immersive search experience

With Petal Search’s Parallel Search function, consumers are able to choose between 2 different viewing modes. With the dual-window mode, consumers view different parts of the search on each screen increasing efficiency. Or if consumers require a better view, single-window mode provides a larger view for a more immersive search experience.

Enjoy an immersive search experience on the large screen of the new HUAWEI Mate Xs 2 with Petal Search’s All-In-One Search. By partnering up with over 3,000 top e-commerce, travel and local merchants, Petal Search optimizes shopping, travel and more than 20 other vertical search categories for users to search from.

Experience true search power when it comes to leisure. Find interesting deals, compare items and prices and much more without having to open additional tabs, when shopping online with Petal Search. Also plan your next holiday with Petal Search by comparing prices of flights and hotels all on one page. Come and take your search experience to the next level!

Based on Huawei’s 1+8+N all-scenario strategy and the adaptation capability of hardware and software, Petal Search aims to provide users with a seamless and consistent search experience.

To download and experience Petal Search, please visit: https://bit.ly/3rpGYGY

Photo – https://mma.prnewswire.com/media/1820758/image_1.jpg

Posted on

JA Solar Achieves Seventh Consecutive “Top Performer” Rank in 2022 PVEL PV Module Reliability Scorecard

BEIJING, May 19, 2022 /PRNewswire/ — Citing outstanding product performance, PV Evolution Labs (“PVEL”) recognized JA Solar as a “Top Performer” for the seventh time in its recently released 2022 PVEL PV Module Reliability Scorecard. PVEL is a leading solar module reliability and performance testing laboratory.

PVEL ranks PV module manufacturers based on Product Qualification Program (PQP) testing over an 18-month period. PQP encompasses tests and analysis on thermal cycling (TC600), damp heat (DH2000), mechanical stress sequence (MSS), potential-induced degradation (PID192), light-induced degradation (LID), light and elevated temperature-induced degradation (LeTID), and more.

Compared to most standardized tests, PQP is more rigorous in terms of both testing conditions and sequences. Consequently, the results obtained are more detailed and significant for practical module application scenarios. PQP results provide solar project developers, investors and asset owners with independent, consistent reliability and performance data for reliable PV product choice and effective supplier management.

The seventh “Top Performer” designation demonstrates JA Solar’s continuous innovation in products and technology.  According to data from a one-year (February 2021-February 2022) energy yield test jointly conducted by JA Solar and TUV Nord, the power generation per watt of JA Solar DeepBlue 3.0 module is about 1.6% higher than that of the super-large current modules.

By prioritizing R&D for PV products and their various applications, JA Solar shows its commitment to promoting the development and application of high-efficiency PV technology. By providing high-quality products to customers worldwide, JA Solar gained recognition in the industry and has been awarded the “Top Brand PV” seals from EUPD Research in Europe, MENA, Chile, Mexico, Australia, and Vietnam.

Posted on

Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics

Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range

Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) —

Summary

  • Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistance
  • The company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own and supplier manufacturing sites – is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance
  • This achievement demonstrates Centrient Pharmaceuticals’ commitment and leadership in the responsible production of antibiotics.

Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral antibiotics product range. This standard covers both Centrient’s sites and its suppliers’ sites. This achievement positions the company as a frontrunner in the industry with the delivery of responsibly-produced antibiotics, which minimize the possible contribution to antimicrobial resistance.

The PNEC discharge target is the concentration of an antibiotic in water at which there is unlikely to be a risk of adverse environmental effects or of antimicrobial resistance (AMR) developing. These scientific, risk-based targets were developed by the AMR Industry Alliance and cover around 120 active pharmaceutical ingredients (APIs) used in antibiotic manufacturing. Each individual antibiotic has a corresponding PNEC value, published in the AMR Industry Alliance table of Recommended PNECs for Risk Assessments (updated periodically).

High concentrations of antibiotic residues in factory wastewater can create hotspots of resistant bacteria which may lead to AMR. While manufacturing is just one of the contributors to the emergence of AMR in the environment, its impact cannot be overlooked. AMR is a major threat to global public health as well as to the healthcare industry. Many standard medical procedures such as organ transplants, chemotherapy, and surgeries such as caesarean sections become much more dangerous without effective antibiotics to prevent and treat infections. Antibiotics are the cornerstone of our modern healthcare system, and complying with PNEC standards enables manufacturers to ensure supply of these critically important medicines does not contribute to the risk of AMR.

The PNEC values are increasingly being recognized as the standard for antibiotic discharge concentrations in water and are expanding beyond Alliance companies and their supply chains. For example, tenders in the UK and Germany (health insurer AOK) include a specific reference to the PNEC discharge targets. Also, companies assessed externally by organizations such as the Access to Medicine Foundation will have public exposure for their performance on PNECs.

As a strong advocate for sustainable manufacturing, Centrient Pharmaceuticals became a founding board member of the AMR Industry Alliance in 2017, working with partners to raise awareness and deliver solutions to the AMR issue. Since then, the company’s own journey to reaching full compliance has included establishing state-of-the-art wastewater treatment facilities at all their sites worldwide and developing tests for measuring antibiotic activity in wastewater streams, leading to a fully clean and PNEC-compliant supply chain.

“We are proud to be the first in our industry to publicly announce PNEC compliance for our oral antibiotics product supply chain.

At Centrient Pharmaceuticals, our commitment to Sustainability is in our DNA – we ensure that the way in which we produce pharmaceuticals has the lowest environmental impact and does not contribute to AMR. We are proud of our PureActives® enzymatic low-carbon technology, ISO 14001 certification of all our sites, and Board positions at the Pharmaceutical Supply Chain Initiative and AMR Industry Alliance.

We will continue to work with customers, suppliers, industry and government decision-makers across the value chain to make the supply and buying of antibiotics sustainable to curb AMR.”, says Rex Clements, CEO at Centrient Pharmaceuticals.

Read our whitepaper ‘Manufacturing sustainable antibiotics for the future’ here.

About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins, and anti-fungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.

We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2,200 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rijswijk (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E-Mail: alice.beijersbergen@centrient.com.
About the AMR Industry Alliance

The AMR Industry Alliance was formed in 2017. With approximately 100 life sciences companies and trade associations, it represents nearly one-third of the volume of sales and the majority of all novel products. Members have committed to report on activities they are undertaking in the areas of research & science, access to antibiotics and appropriate use of these, as well as responsible environmental manufacturing to tackle the rapid spread of antimicrobial resistance. If AMR remains unchecked, the annual death toll could climb from 700,000 each year to 10 million by 2050 and the economic impacts could be on par with those of the 2008 financial crisis. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap for Progress on Combating AMR and measures progress made in the fight against AMR.
Forward-looking statements

This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.

Alice Beijersbergen
Centrient Pharmaceuticals
+31 (6) 823 579 56
alice.beijersbergen@centrient.com
Posted on

CGTN: China reaffirms commitment to high-standard opening-up

BEIJING, May 19, 2022 /PRNewswire/ — China on Wednesday reaffirmed its commitment to high-standard opening-up and pledged to foster a business environment based on market principles.

“I wish to reiterate that China’s resolve to open up at a high standard will not change, and that the door of China will open still wider to the world,” Chinese President Xi Jinping said when addressing the conference of the 70th anniversary of the China Council for the Promotion of International Trade (CCPIT) and the Global Trade and Investment Promotion Summit via video link.

“China will continue to foster an enabling business environment that is based on market principles, governed by law and up to international standards,” Xi said.

The world’s second-largest economy will pursue high-standard implementation of the Regional Comprehensive Economic Partnership (RCEP) agreement and high-quality Belt and Road cooperation and offer more market, investment and growth opportunities to the global business community, he said.

Despite challenges posed by the prolonged COVID-19 pandemic, China achieved a strong trade performance in the first quarter of the year, with total goods imports and exports surging 29.2 percent year on year to 8.47 trillion yuan (about $1.25 trillion), data from General Administration of Customs showed.

In the first quarter, China’s trade with countries along the Belt and Road rose 21.4 percent year on year to reach 2.5 trillion yuan (about $370 billion). The country’s trade with the other 14 RCEP members amounted to 2.67 trillion yuan (about $395 billion), up 22.9 percent year on year and accounting for 31.5 percent of its total imports and exports during the period.

Since its establishment in 1952, the CCPIT has played an important role in strengthening the bond of interests between Chinese and foreign enterprises, promoting international economic and trade exchanges and promoting the development of relations, Xi said.

The 70-year journey of the CCPIT has been “an epitome of China’s ever-expanding opening-up endeavor, and an important witness of how businesses from different countries could share in development opportunities and benefit from win-win cooperation,” he added.

Xi calls for making ‘pie’ of cooperation bigger

Noting that economic globalization is experiencing headwinds and the world is entering a new period of volatility and transformation, the president made several proposals.

Joint efforts are needed in defeating the pandemic, he said, adding that it is important to put people and their lives first, actively engage in international cooperation on vaccine R&D, production and distribution, and bolster global public health governance.

On reinvigorating trade and investment, he stressed supporting the World Trade Organization (WTO)-centered multilateral trading regime, ensuring security and stability of the global industrial and supply chains, and making the “pie” of cooperation bigger to allow development gains to better trickle down to people of all countries.

He also emphasized the efforts to unleash the power of innovation in driving development, calling for fostering an open, fair, equitable and non-discriminatory environment for scientific and technological development.

On improving global governance, he said true multilateralism must be upheld.

“We should choose dialogue over confrontation, tear down walls rather than erect walls, pursue integration instead of decoupling, opt for inclusiveness, not exclusion, and guide reforms of the global governance system with the principle of fairness and justice,” he said.

https://news.cgtn.com/news/2022-05-18/President-Xi-reiterates-China-s-resolve-to-open-up-at-high-standard-1a8MutaXcli/index.html

Posted on

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

  • Dante Labs is a Global Leader in Genomics and Precision Medicine
  • Mainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer

BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC).

Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals. Inherent to Dante Lab’s business model is managing state-of-the-art genomic sequencing laboratories in multiple international regions, and operating a robust e-commerce platform.

“As a young company with the goal of bringing to market important diagnostic tools to help treat and prevent cancer indications, it’s an absolute pleasure to partner with an industry leader such as Dante Labs,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Our differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility requires alliances with like-minded companies such as Dante Labs, who share our passion for forward-thinking diagnostic test development and marketing strategies.”

The partnership will first launch ColoAlert in Italy and UAE using Dante’s various established commercial channels. Samples will initially be processed at Mainz’s in-house facility and then Dante will purchase Mainz’s CE-IVD polymerase chain reaction (PCR) assay kits and transition all test processing to Dante’s wholly-owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) to offer localized service and support.

“We are excited by the opportunity to align with Mainz and represent ColoAlert in these initial markets,” commented Andrea Riposati, Chief Executive Officer of Dante Labs. “Both the product and the Company mirror our mission to develop and market top-tier preventive health solutions and use new channels to make innovative tests available to more patients around the world. With the launch of our enhanced ecommerce platforms for advanced diagnostics, ColoAlert is an amazing product to deliver more personalized medicine.”

ColoAlert is currently marketed across Europe, and the partnership with Dante Labs marks the test’s initial launch in the Middle East. Mainz will continue to develop commercial and R&D partnerships with companies that lead the field of health screening with a particular focus on stool diagnostics.

About ColoAlert

ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the Europe Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.

*Dollinger MM et al. (2018)

About Colorectal Cancer

Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US-based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.

About Mainz Biomed N.V.

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

For more information please visit www.mainzbiomed.com

For media enquiries, please contact press@mainzbiomed.com

For investor enquiries, please contact ir@mainzbiomed.com

About Dante Labs
Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contact:

Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantelabs.com

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 as well as the Prospectus filed on January 21, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Posted on

Advance Local is New Sophi.io Customer

TORONTO, May 18, 2022 (GLOBE NEWSWIRE) — Advance Local, one of the largest media groups in the United States operating 10 leading news and information organizations and reaching 55 million people monthly, has quadrupled their subscription goal using Sophi Content Paywall Engine. Faced with advertising pressures exacerbated by the Coronavirus, Advance Local increased subscription conversions 45% using Sophi.io, an AI-powered automation, optimization and prediction platform developed by The Globe and Mail. Their success with Sophi has also earned them a spot as a finalist in the Digiday Media Awards, announced this week.

Neil Katz, Chief Customer Officer at Advance Local, said, “We wanted to see how much farther Sophi could take us, so we tested Sophi Content Paywall on one of our largest sites. The results were transformative. We were hoping for a 10% lift in conversion rate and Sophi delivered four times that result. We’re continuing to roll out Sophi solutions across more of our sites as we speak.”

Advance started using Sophi Content Paywall Engine on one of its largest sites, cleveland.com, to get better insights into the value of their content and fuel their new subscription business. The technology uses advanced natural language processing (NLP) to analyze every piece of content and select which articles to put behind a paywall. It picks only those articles where the subscription revenue opportunity outweighs the advertising revenue forgone.

During an experiment where Advance could see how Sophi performed side by side with their existing paywall, Sophi presented roughly the same amount of paywalls and generated a 45% lift in the total conversion rate, while also uncovering pockets of content that editors didn’t anticipate would generate subscriptions.

John Hassell, Senior Vice President and Editorial Director at Advance Local, said, “We wanted to see if Sophi’s content paywall could increase subscriber acquisition by 10% and it blew that goal out of the water. We’re feeling good about the platform and the way it is showing us just how valuable our editorial content is to our audience.”

Advance Local is also a finalist in the Digiday Media Awards, in the category of Best Subscription or Membership Product, for their work using Sophi Content Paywall Engine.

“Advance Local is an incredibly innovative organization that we’ve watched push the boundaries and we’re very excited to be working with them,” said Mike O’Neill, Co-Founder and CEO of Sophi.io. “We’re seeing great value come from the content paywall they’ve implemented and we’re excited to introduce some other cutting edge technology into this very strong brand.”

About Advance Local

Advance Local (www.advancelocal.com) is one of the largest media groups in the United States. It operates 10 leading news and information organizations and reaches 55 million people monthly across multiple platforms with its high-quality journalism. They are dedicated to unrivaled local journalism that improves the lives of millions of people.

About Sophi.io

Sophi.io (https://www.sophi.io) was developed by The Globe and Mail to help content publishers make important strategic and tactical decisions. It is a suite of AI and ML-powered automation, optimization and prediction solutions that include Sophi Site Automation, Sophi for Paywalls and Sophi for First Party Data. Sophi also powers one-click automated laydown of template-free print publishing. Sophi is designed to improve the metrics that matter most to your business, such as subscriber retention and acquisition, engagement, recency, frequency and volume.

Contact Us

Jamie Rubenovitch
Head of Marketing, Sophi.io
The Globe and Mail        
jrubenovitch@globeandmail.com
416-585-3355